Authorizes insurance policies which provide coverage for prescription drugs where cost-sharing obligations are determined by category of prescription drugs to offer a program to insureds that utilizes rebates or discounts to lower an insured's cost-sharing for prescription drugs if the insured's cost-sharing under such program would be more favorable than the cost-sharing that would otherwise be applicable to the prescription drug.
Impact
If enacted, S07900 would have significant implications for existing insurance policies related to prescription drugs. It would unify regulations on how cost-sharing is determined for prescription drugs among various types of insurance providers, including health maintenance organizations and medical expense indemnity corporations. State laws would be updated to allow these entities the flexibility to offer enhanced programs that reduce the financial burden on consumers, potentially improving access to medications for many New Yorkers.
Summary
Bill S07900, introduced in the New York Senate, aims to amend the insurance and public health laws concerning prescription drug coverage. Specifically, it seeks to authorize insurance policies that provide coverage for prescription drugs to implement a program utilizing rebates or discounts to lower the cost-sharing obligations for insured individuals. The bill mandates that if such a program results in more favorable cost-sharing than what would typically apply, it shall be made available to insureds. This legislation is positioned as a means to improve affordability for patients needing medication.
Contention
While supporters claim that S07900 could enhance the affordability of essential prescription drugs and improve access to necessary treatments, there may be concerns regarding the administration of such rebate programs. Critics could argue that elevation of cost-sharing obligations could lead to confusion for consumers about their out-of-pocket expenses, especially if not transparently communicated. Moreover, there might be debates over how rebates and discounts could affect the overall pricing structures set by pharmaceutical companies and the insurance industry overall.
Same As
Authorizes insurance policies which provide coverage for prescription drugs where cost-sharing obligations are determined by category of prescription drugs to offer a program to insureds that utilizes rebates or discounts to lower an insured's cost-sharing for prescription drugs if the insured's cost-sharing under such program would be more favorable than the cost-sharing that would otherwise be applicable to the prescription drug.
Authorizes insurance policies which provide coverage for prescription drugs where cost-sharing obligations are determined by category of prescription drugs to offer a program to insureds that utilizes rebates or discounts to lower an insured's cost-sharing for prescription drugs if the insured's cost-sharing under such program would be more favorable than the cost-sharing that would otherwise be applicable to the prescription drug.
Prohibiting certain health insurers from requiring cost-sharing for nonopioid prescription drugs or providing less favorable coverage for such drug than that for opioid or narcotic prescription drugs for the treatment of pain.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.